233 related articles for article (PubMed ID: 34839992)
1. Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection.
Dinc HO; Saltoglu N; Can G; Balkan II; Budak B; Ozbey D; Caglar B; Karaali R; Mete B; Tuyji Tok Y; Ersoy Y; Ahmet Kuskucu M; Midilli K; Ergin S; Kocazeybek BS
Vaccine; 2022 Jan; 40(1):52-58. PubMed ID: 34839992
[TBL] [Abstract][Full Text] [Related]
2. Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required.
Balkan İİ; Dinc HO; Can G; Karaali R; Ozbey D; Caglar B; Beytur AN; Keskin E; Budak B; Aydogan O; Mete B; Ergin S; Kocazeybek B; Saltoglu N
Ir J Med Sci; 2023 Feb; 192(1):19-25. PubMed ID: 35344137
[TBL] [Abstract][Full Text] [Related]
3. [The Second Shot of CoronaVac Vaccine May Cause Reduction of Antibody Levels in People who Previously had COVID-19].
Topkaya AE; Keskin AÜ; Dalan AB; Çıragil P
Mikrobiyol Bul; 2022 Jan; 56(1):139-142. PubMed ID: 35088968
[TBL] [Abstract][Full Text] [Related]
4. Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers.
Kitro A; Sirikul W; Thongkum W; Soponpong S; Yasamut U; Kiratipaisarl W; Kosai A; Kasinrerk W; Tayapiwatana C; Srithanaviboonchai K
Vaccine; 2022 May; 40(21):2915-2924. PubMed ID: 35430106
[TBL] [Abstract][Full Text] [Related]
5. Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers.
Bayram A; Demirbakan H; Günel Karadeniz P; Erdoğan M; Koçer I
J Med Virol; 2021 Sep; 93(9):5560-5567. PubMed ID: 34019704
[TBL] [Abstract][Full Text] [Related]
6. [Factors Affecting Side Effects, Seroconversion Rates and Antibody Response After Inactivated SARS-CoV-2 Vaccination in Healthcare Workers].
Şenol Akar Ş; Akçalı S; Özkaya Y; Gezginci FM; Cengiz Özyurt B; Deniz G; Karadağ Yalçın F; Özer D; Dündar Erbay P; Eser E
Mikrobiyol Bul; 2021 Oct; 55(4):519-538. PubMed ID: 34666653
[TBL] [Abstract][Full Text] [Related]
7. Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?
Stellini R; Gianello R; Gomarasca W
Infection; 2022 Dec; 50(6):1573-1577. PubMed ID: 35391649
[TBL] [Abstract][Full Text] [Related]
8. Assessing humoral immune response after two doses of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthcare workers.
Demirbakan H; Koçer I; Erdoğan M; Bayram A
Public Health; 2022 Apr; 205():1-5. PubMed ID: 35219127
[TBL] [Abstract][Full Text] [Related]
9. [Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study].
Özgür D; Tütüncü EE
Mikrobiyol Bul; 2022 Jan; 56(1):36-48. PubMed ID: 35088958
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine.
Yavuz E; Günal Ö; Başbulut E; Şen A
J Med Virol; 2022 Aug; 94(8):3768-3775. PubMed ID: 35434796
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies.
Sughayer MA; Souan L; Abu Alhowr MM; Al Rimawi D; Siag M; Albadr S; Owdeh M; Al Atrash T
Vaccine; 2022 May; 40(20):2841-2847. PubMed ID: 35397946
[TBL] [Abstract][Full Text] [Related]
12. [Investigation of SARS-CoV-2-Specific Humoral and Cellular Immunity Values in Health Care Workers with COVID-19 Disease and Administered with COVID-19 Vaccine].
Keskin AÜ; Dalan AB; Çıragil P; Topkaya AE
Mikrobiyol Bul; 2022 Jul; 56(3):480-492. PubMed ID: 35960239
[TBL] [Abstract][Full Text] [Related]
13. Monitoring SARS CoV-2 antibodies positivity in healthcare workers after inactivated CoronaVac
Demir M; Çalışkan A; Kaleli İ; Dönmez B; Er H; Ergin Ç
Germs; 2022 Dec; 12(4):507-518. PubMed ID: 38021180
[TBL] [Abstract][Full Text] [Related]
14. Heterologous booster COVID-19 vaccination elicited potent immune responses in HCWs.
Saltoğlu N; Dinç HÖ; Balkan İİ; Can G; Özbey D; Beytur AN; Keskin E; Budak B; Aydoğan O; Mete B; Karaali R; Ergin S; Kocazeybek B
Diagn Microbiol Infect Dis; 2022 Oct; 104(2):115758. PubMed ID: 35878507
[TBL] [Abstract][Full Text] [Related]
15. Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers.
Soysal A; Gönüllü E; Karabayır N; Alan S; Atıcı S; Yıldız İ; Engin H; Çivilibal M; Karaböcüoğlu M
Hum Vaccin Immunother; 2021 Nov; 17(11):3876-3880. PubMed ID: 34324409
[TBL] [Abstract][Full Text] [Related]
16. Antibody response after two doses of homologous or heterologous SARS-CoV-2 vaccines in healthcare workers at health promotion centers: A prospective observational study.
Nah EH; Cho S; Park H; Kim S; Noh D; Kwon E; Cho HI
J Med Virol; 2022 Oct; 94(10):4719-4726. PubMed ID: 35655438
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients.
Laham G; Martínez AP; Rojas Gimenez W; Amaya L; Abib A; Echegoyen N; Díaz C; Lucero A; Martelli A; Videla C; Neukam K; Di Lello FA
J Nephrol; 2023 Apr; 36(3):861-872. PubMed ID: 36152219
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
19. Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers.
Oliveira-Silva J; Reis T; Lopes C; Batista-Silva R; Ribeiro R; Marques G; Pacheco V; Rodrigues T; Afonso A; Pinheiro V; Araújo L; Rodrigues F; Antunes I
Vaccine; 2022 Jan; 40(4):650-655. PubMed ID: 34952755
[TBL] [Abstract][Full Text] [Related]
20. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
